IGF-1 LR3 and Retatrutide Together: What the Research Literature Covers

The short answer on the combination

Searches such as "can you take IGF-1 LR3 with retatrutide" assume that somewhere in the literature the two compounds have been studied side by side. They have not. No published clinical trial, and no peer-reviewed animal study identifiable in the indexed literature, has administered IGF-1 LR3 together with retatrutide or reported any outcome for that pairing. Everything written below therefore describes each compound separately, because that is the only evidence that exists.

The two also occupy very different evidence categories. Retatrutide has been characterised from molecular discovery through phase 1, phase 2 and now phase 3 registrational trials, with results published in Cell Metabolism, The Lancet, the New England Journal of Medicine and Nature Medicine. IGF-1 LR3 has no comparable human trial programme. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medication question.

What retatrutide is

Retatrutide (development code LY3437943) is a single-molecule agonist at three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Researchers described its discovery, receptor pharmacology and first clinical proof of concept in a 2022 report that traced the molecule from preclinical characterisation into early human study, including a pharmacokinetic profile compatible with once-weekly administration (PMID 35985340). Review articles have since framed the addition of glucagon receptor activity, on top of the incretin activity shared with earlier agents, as the feature that distinguishes it from GLP-1 mono-agonists and GIP/GLP-1 dual agonists (PMID 39515565, PMID 40563436).

Early-phase clinical work

A phase 1b multiple-ascending-dose trial in people with type 2 diabetes ran for 12 weeks and reported reductions in glycated haemoglobin and body weight relative to placebo, with gastrointestinal events the most frequently observed adverse events (PMID 36354040). Those early data informed the dose ranges later carried into phase 2.

Phase 2 in obesity

The phase 2 obesity trial enrolled 338 adults and randomly assigned them to placebo or retatrutide at 1, 4, 8 or 12 mg once weekly for 48 weeks, with several arms differing in starting dose and escalation speed. At 48 weeks the study reported a least-squares mean change in body weight of about −24.2% in the 12 mg group compared with about −2.1% with placebo, with intermediate reductions at lower doses (PMID 37366315). Researchers noted that weight reduction had not clearly plateaued by the end of the treatment period.

Type 2 diabetes

A separate phase 2 trial in adults with type 2 diabetes compared retatrutide across a dose range with both placebo and dulaglutide 1.5 mg over 36 weeks, and reported greater reductions in glycated haemoglobin and body weight in the higher retatrutide groups than in either comparator (PMID 37385280). A phase 3 trial, TRANSCEND-T2D-1, subsequently evaluated retatrutide in people with type 2 diabetes and inadequate glycaemic control on diet and exercise alone, extending the same efficacy and safety questions into a registrational setting (PMID 42250575). A separate publication set out the rationale and design of the TRIUMPH phase 3 programme, which covers obesity, obstructive sleep apnoea and knee osteoarthritis (PMID 41090431).

Liver fat

A randomised phase 2a trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease measured liver fat content by imaging and reported large relative reductions at 24 and 48 weeks in the retatrutide groups, with most participants in the higher-dose groups reaching liver fat below the 5% threshold used to define normal (PMID 38858523). Researchers presented these results as hypothesis-generating for larger hepatology endpoints rather than definitive.

Body composition — the substudy that matters to this question

The reason the IGF-1 LR3 question surfaces at all is body composition. A substudy of the phase 2 type 2 diabetes trial used imaging to separate fat mass from lean mass during retatrutide treatment. The study reported that reductions in fat mass, including visceral fat, accounted for the majority of total weight lost, with proportionally smaller reductions in lean mass (PMID 40609566). This is the only published dataset in the retatrutide literature that directly addresses the lean-tissue question that drives interest in growth-factor compounds.

Where retatrutide sits against other agents

A Bayesian network meta-analysis of GLP-1 receptor agonists, dual agonists and retatrutide in adults with overweight or obesity ranked retatrutide highest for percentage weight reduction among the compared agents, while noting the differing trial durations and populations behind the indirect comparison (PMID 40685589). A separate systematic review and meta-analysis of randomised controlled trials reported significant weight reduction versus placebo alongside a higher incidence of gastrointestinal adverse events (PMID 40291085).

Adverse Events in Retatrutide Trials: What Studies Report

Across the published trials, gastrointestinal events dominated the adverse-event tables. In the phase 2 obesity trial, researchers reported that nausea, diarrhoea, vomiting and constipation were the most common events, that they were mostly mild to moderate, that they clustered during dose escalation, and that they were partially mitigated by a lower starting dose and slower escalation (PMID 37366315). The phase 1b multiple-ascending-dose trial reported the same gastrointestinal pattern in people with type 2 diabetes (PMID 36354040).

The pooled meta-analysis reported that gastrointestinal adverse events occurred more frequently with retatrutide than with placebo and were dose-related (PMID 40291085). Review articles have flagged heart rate changes, glucagon-receptor-related metabolic effects and the absence of long-term outcome data as areas still under evaluation in the phase 3 programme (PMID 40563436, PMID 41090431).

What IGF-1 LR3 is

IGF-1 LR3, or Long R3 IGF-1, is a laboratory-modified analogue of human insulin-like growth factor-1. The modification consists of a 13-amino-acid extension at the N-terminus and an arginine substitution at position three of the native sequence. It was originally developed as a cell-culture reagent — a supplement used to support mammalian cell growth in bioprocessing — and it is distributed under research-use-only labelling. It is not an approved medicine in the United States, the European Union or any comparable jurisdiction, and it has no marketing authorisation for any human indication.

Recombinant human IGF-1 itself exists as an approved product (mecasermin) for severe primary IGF-1 deficiency, but that is a different molecule with its own regulatory dossier, and the approval of mecasermin says nothing about the safety or effects of the LR3 analogue. IGF-1 and its analogues also appear on the World Anti-Doping Agency Prohibited List under the peptide hormones, growth factors and related substances category, which is a regulatory fact rather than a statement about efficacy.

Critically for this page: the verified reference set used here contains no controlled human trial of IGF-1 LR3, and PeptideU does not summarise dose figures or physiological effects it cannot attach to a citable published study. Anything circulating online that presents IGF-1 LR3 dosing schedules, timing schemes or expected outcomes is not drawn from a peer-reviewed clinical trial record.

Why the combination question comes up

The pairing is not a research hypothesis from any published paper. It appears to originate in online discussion, and the reasoning behind it is usually some version of the following:

• Rapid weight loss raises body composition questions. Because the phase 2 obesity trial reported weight reduction of roughly a quarter of body weight at the highest dose over 48 weeks (PMID 37366315), people ask what fraction of that loss is fat versus lean tissue.
• One substudy has looked at that directly. Researchers reported that fat mass accounted for the majority of weight lost, with smaller lean-mass reductions (PMID 40609566). That finding is about retatrutide alone; it does not evaluate any add-on compound.
• IGF-1 has a reputation for anabolic signalling. That reputation drives the assumption that an IGF-1 analogue would offset lean-mass loss. No published study has tested that assumption alongside retatrutide or any other incretin-based agent.
• Availability differs from evidence. Research-use-only labelling makes a compound purchasable in some markets without making it studied.

Side-by-side: evidence status

Questions the literature has not answered

1. Whether co-administration of an IGF-1 analogue alters the metabolic effects reported for retatrutide in trials such as the phase 2 obesity study (PMID 37366315). No study has looked.
2. Whether lean-mass changes described in the body composition substudy would differ with any add-on agent (PMID 40609566). Unstudied.
3. Whether the gastrointestinal adverse-event profile reported across trials and meta-analyses would be modified by a second compound (PMID 40291085). Unstudied.
4. What a safe or unsafe exposure to IGF-1 LR3 looks like in humans at all. No controlled trial record exists in the reference set to answer that.

When a combination has produced no published data, the honest description is that the evidence is absent — not that it is favourable, and not that it is unfavourable. Absence of study is not the same as demonstrated safety, and it is not the same as demonstrated harm. Readers with questions about any specific compound, alone or in combination, are directed to a licensed clinician who can consider individual medical context.

References

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (Lancet, 2022)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (Lancet Diabetes & Endocrinology, 2025)
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA (Obesity, 2025)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings, Baylor University Medical Center, 2025)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• The power of three: Retatrutide's role in modern obesity and diabetes therapy (European Journal of Pharmacology, 2024)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (Lancet, 2026)